These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8189029)

  • 1. Experience with Eudragit-S coated mesalamine (Asacol) in inflammatory bowel disease: adverse events.
    Nichols TW
    J Clin Gastroenterol; 1994 Mar; 18(2):181. PubMed ID: 8189029
    [No Abstract]   [Full Text] [Related]  

  • 2. Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.
    Faber SM; Korelitz BI
    J Clin Gastroenterol; 1993 Oct; 17(3):213-8. PubMed ID: 8228082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid].
    Frol'kis AV
    Ter Arkh; 1996; 68(2):75-7. PubMed ID: 8771669
    [No Abstract]   [Full Text] [Related]  

  • 4. Resin-coated 5-aminosalicylic acid (Asacol) in rheumatoid arthritis.
    Situnayake RD; McConkey B
    Br J Rheumatol; 1985 May; 24(2):226-7. PubMed ID: 3995220
    [No Abstract]   [Full Text] [Related]  

  • 5. Asacol (mesalamine).
    Claussen D
    Gastroenterol Nurs; 1992 Aug; 15(1):33-4. PubMed ID: 1525190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP; Wilkinson SP
    Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
    Nakshabendi IM; Duncan A; Russell RI
    Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatitis induced by mesalamine.
    Erdkamp F; Houben M; Ackerman E; Breed W; van Spreeuwel J
    Neth J Med; 1992 Aug; 41(1-2):71-3. PubMed ID: 1407243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.
    Dew MJ; Hughes P; Harries AD; Williams G; Evans BK; Rhodes J
    Br Med J (Clin Res Ed); 1982 Oct; 285(6347):1012. PubMed ID: 6127137
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experiences with phase III studies in the area of gastroenterology].
    Kruis W
    Verh Dtsch Ges Inn Med; 1991; 97():503-6. PubMed ID: 1687301
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of a novel tablet-in-capsule formulation of mesalamine for inflammatory bowel disease.
    Patel MM; Amin AF
    Pharm Dev Technol; 2013; 18(2):390-400. PubMed ID: 22304735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
    Sninsky CA; Cort DH; Shanahan F; Powers BJ; Sessions JT; Pruitt RE; Jacobs WH; Lo SK; Targan SR; Cerda JJ
    Ann Intern Med; 1991 Sep; 115(5):350-5. PubMed ID: 1863024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.
    Järnerot G
    Drugs; 1989 Jan; 37(1):73-86. PubMed ID: 2651087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Salicylic derivatives in the clinical treatment of inflammatory bowel disease: new perspectives].
    Damião AO; Sipahi AM
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(5):271-8. PubMed ID: 2576896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience.
    Tolia V; Massoud N; Klotz U
    J Pediatr Gastroenterol Nutr; 1989 Apr; 8(3):333-8. PubMed ID: 2565380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Side effects of 5-aminosalicylic acid].
    Marteau P; Cellier C
    Gastroenterol Clin Biol; 1997; 21(5):377-86. PubMed ID: 9208013
    [No Abstract]   [Full Text] [Related]  

  • 17. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.
    Lowry PW; Szumlanski CL; Weinshilboum RM; Sandborn WJ
    Gastroenterology; 1999 Jun; 116(6):1505-6. PubMed ID: 10391741
    [No Abstract]   [Full Text] [Related]  

  • 18. [5-aminosalicylic acid-associated pancreatitis].
    Tromm A; May B
    Dtsch Med Wochenschr; 1991 Jul; 116(28-29):1125. PubMed ID: 2065601
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aminosalicylates in the treatment of idiopathic inflammatory bowel disease].
    Lukás K
    Vnitr Lek; 1996 Feb; 42(2):117-9. PubMed ID: 8686186
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG; Healey JN; Reynolds JR
    Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.